0 stringlengths 16 494 | embeddings listlengths 384 384 |
|---|---|
sulin pump use in people with type 1 dia-betes, reductions in A1C levels have been\nreported in some studies (247,250). More\nrecently, real-world reports have shownreduction of A1C levels and reduction oftotal daily insulin dose in individuals withtype 2 diabetes initiating insulin pump\ntherapy (251). Use of insulin ... | [
-0.0945996418595314,
-0.04479609429836273,
-0.04262889176607132,
0.04100595414638519,
-0.09370778501033783,
-0.016566049307584763,
0.0676947757601738,
0.05913560092449188,
-0.03762459009885788,
-0.04875564202666283,
-0.017299866303801537,
0.09331308305263519,
-0.08074691146612167,
0.028309... |
therapy (251). Use of insulin pumps in in-\nsulin-requiring people with any type of di-abetes may improve user satisfaction andsimplify therapy (180,245).\nFor people with diabetes judged to be\nclinically insulin de ficient who are treated\nwith an intensive insulin therapy, the\npresence or absence of measurable | [
-0.034518174827098846,
0.01905495673418045,
-0.05935147404670715,
0.02818039059638977,
-0.06713230907917023,
-0.02844931371510029,
0.14976820349693298,
0.11775020509958267,
-0.07774306833744049,
-0.04020990431308746,
-0.04726283252239227,
0.09732916951179504,
-0.0049229394644498825,
-0.032... |
presence or absence of measurable\nC-peptide levels does not correlatewith response to therapy (180). A low\nC-peptide value should not be requiredfor insulin pump coverage in individu-als with type 2 diabetes.\nThe use of insulin pumps and AID sys-\ntems in type 2 diabetes is still limited;\nhowever, real-world studie... | [
0.02311386540532112,
-0.062072139233350754,
-0.09685895591974258,
0.0009044946637004614,
0.002844266127794981,
0.02212398871779442,
0.04367803409695625,
0.12239047884941101,
0.03448265790939331,
-0.02523386850953102,
0.04776008427143097,
0.025401614606380463,
-0.03509911522269249,
0.064975... |
however, real-world studies have shown\nbene fits of these technologies in these\nindividuals (243,252).\nAlternative insulin delivery options in\npeople with type 2 diabetes may include\ndisposable patch-like devices, which pro-\nvide either a CSII of rapid-acting insulin(basal) with bolus insulin in 2-unit incre- | [
-0.062192920595407486,
-0.007302672136574984,
-0.04578123614192009,
0.03154919669032097,
-0.045021865516901016,
-0.06346401572227478,
0.07200631499290466,
0.08467128872871399,
-0.04948443919420242,
0.036682140082120895,
0.014013674110174179,
0.05268515646457672,
-0.03984856233000755,
0.017... |
ments at the press of a button or bolus in-\nsulin only delivered in 2-unit increments\nused in conjunction with basal insulin in-\njections (246,248,253,254). Use of an in-sulin pump as a means of insulin delivery\nis an individual choice for people with dia-\nbetes and should be considered an option\nin those who are... | [
-0.07007424533367157,
-0.02605292573571205,
-0.1177145391702652,
0.0010593913029879332,
-0.10759955644607544,
-0.03211114928126335,
0.12143561989068985,
0.04818329960107803,
-0.03365827724337578,
-0.019923565909266472,
0.023128235712647438,
0.06119179353117943,
-0.07041831314563751,
0.0396... |
in those who are capable of safely using\nthe device.\nDo-It-Yourself Closed-Loop Systems\nRecommendation\n7.31 Individuals with diabetes may be\nusing systems not approved by the\nFDA, such as do-it-yourself closed-loopsystems and others; health care pro-\nfessionals cannot prescribe these sys- | [
-0.027576230466365814,
-0.01972261257469654,
-0.10084091871976852,
-0.05870278552174568,
-0.008936431258916855,
-0.024432625621557236,
0.14131386578083038,
0.09733987599611282,
-0.0015637080650776625,
-0.005230007693171501,
0.033780209720134735,
0.10514751821756363,
-0.002619584556668997,
... |
fessionals cannot prescribe these sys-\ntems but should assist in diabetesmanagement to ensure the safety ofpeople with diabetes. E\nSome people with type 1 diabetes have\nbeen using do-it-yourself systems that\ncombine an insulin pump and an rtCGMwith a controller and an algorithm de-\nsigned to automate insulin deliv... | [
-0.07428303360939026,
-0.02061927504837513,
-0.11317144334316254,
0.004576763138175011,
-0.03501496464014053,
-0.011311111971735954,
0.1479799449443817,
0.08329029381275177,
-0.08017411828041077,
-0.010421196930110455,
-0.014121023938059807,
0.09666295349597931,
-0.0460013821721077,
0.0455... |
signed to automate insulin delivery\n(255–259). Data are emerging on the\nsafety and effectiveness of speci fics y s -\ntems (260,261). However, these sys-tems are not approved by the FDA,\nalthough efforts are underway to ob-\ntain regulatory approval for some of\nthem. The information on how to set | [
-0.014175149612128735,
-0.014830946922302246,
-0.12577714025974274,
0.01893806830048561,
-0.02914159558713436,
-0.02502814307808876,
0.09021797776222229,
0.08797672390937805,
-0.10210424661636353,
0.025772204622626305,
0.006217502057552338,
0.015912504866719246,
-0.03489311784505844,
0.042... |
them. The information on how to set\nup and manage these systems is freelyavailable on the internet, and there are\ninternet groups where people inform\neach other as to how to set up and use\nthem. Although health care professio-\nnals cannot prescribe these systems, itis crucial to keep people with diabetes\nsafe if ... | [
-0.04911186546087265,
0.0029767074156552553,
-0.08907527476549149,
-0.03706427663564682,
-0.04882117360830307,
0.053291793912649155,
0.06491231173276901,
0.0961858332157135,
0.029158003628253937,
0.01225370541214943,
0.0012987827649340034,
0.06347928941249847,
-0.014751801267266273,
-0.021... |
safe if they are using these methods\nfor AID. Part of this entails ensuring\np e o p l eh a v eab a c k u pp l a ni nc a s eo f\npump failure. Additionally, in most do-it-yourself systems, insulin doses are\nadjusted based on the pump settingsdiabetesjournals.org/care Diabetes Technology S135\n©AmericanDiabetesAssocia... | [
-0.03240368142724037,
0.02787928842008114,
-0.09528680145740509,
-0.022213609889149666,
-0.03407106548547745,
0.0029067012947052717,
0.07117138057947159,
0.05052901431918144,
-0.09667370468378067,
-0.023844873532652855,
-0.024913569912314415,
0.09770668298006058,
-0.02962956763803959,
0.01... |
for basal rates, carbohydrate ratios,\ncorrection doses, and insulin activity.Therefore, these settings can be evalu-\nated and modi fied based on the indi-\nvidual’ s insulin requirements.\nDigital Health Technology\nRecommendation\n7.32 Systems that combine technol-\nogy and online coaching can be ben-\neficial in mana... | [
0.0013778702123090625,
0.014766932465136051,
-0.08287466317415237,
0.019083930179476738,
-0.06893017888069153,
0.026103081181645393,
0.07098134607076645,
0.09131681174039841,
-0.059020888060331345,
-0.012051006779074669,
-0.020361702889204025,
0.013873833231627941,
-0.05183011665940285,
-0... |
eficial in managing prediabetes and\ndiabetes for some individuals. B\nIncreasingly, people are turning to the in-\nternet for advice, coaching, connection,\nand health care. Diabetes, partly because itis both common and numeric, lends itself\nto the development of apps and online | [
-0.015780577436089516,
-0.005000495817512274,
-0.04832373186945915,
0.005590657703578472,
-0.03326902166008949,
0.01212196797132492,
0.09831812232732773,
0.1147664412856102,
0.02178586646914482,
0.014781502075493336,
-0.07740116864442825,
0.06087344512343407,
-0.07897333055734634,
-0.04198... |
to the development of apps and online\nprograms. Recommendations for develop-ing and implementing a digital diabetes\nclinic have been published (262). The FDA\napproves and monitors clinically validated,\ndigital, and usually online health technol-\nogies intended to treat a medical or psy-chological condition; these ... | [
-0.04870178550481796,
-0.04842684417963028,
-0.11793912202119827,
-0.014551190659403801,
-0.0587182380259037,
0.024455344304442406,
0.05026361346244812,
0.13917230069637299,
-0.030024630948901176,
0.03452586382627487,
-0.07204879075288773,
0.0596417561173439,
-0.052210189402103424,
-0.0312... |
digital therapeutics or “digiceuticals ”(fda\n.gov/medical-devices/digital-health-center-\nexcellence/device-software-functions-\nincluding-mobile-medical-applications) (263).\nOther applications, such as those that as-sist in displaying or storing data, encour-\nage a healthy lifestyle or provide limited\nclinical dat... | [
-0.06963449716567993,
-0.006494087632745504,
-0.053873252123594284,
-0.1022474467754364,
-0.07554419338703156,
-0.05810527503490448,
-0.01164491567760706,
0.15757887065410614,
0.01010279729962349,
0.019535288214683533,
-0.02913476713001728,
0.041421011090278625,
0.011479205451905727,
-0.03... |
clinical data support. Therefore, it is possi-\nble to find apps that have been fully re-\nviewed and approved by the FDA and\nothers designed and promoted by people\nwith relatively little skill or knowledge in\nthe clinical treatment of diabetes. Thereare insuffi cient data to provide recom-\nmendations for speci fic ap... | [
-0.051767583936452866,
0.0006898827850818634,
-0.029469884932041168,
-0.020656367763876915,
-0.03296086564660072,
0.026237698271870613,
0.01800375245511532,
0.10356251895427704,
-0.030163418501615524,
0.01139963511377573,
-0.0626620501279831,
0.04840683937072754,
-0.05697717145085335,
-0.0... |
mendations for speci fic apps for diabetes\nmanagement, education, and support inthe absence of RCTs and validation of\napps unless they are FDA cleared.\nAn area of particular importance is\nthat of online privacy and security. Es-\ntablished cloud-based data aggregator\nprograms, such as Tidepool, Glooko, andothers, h... | [
-0.08969100564718246,
0.02179490216076374,
-0.07293806225061417,
-0.059490643441677094,
0.0029883987735956907,
0.035307422280311584,
0.05648012086749077,
0.09629510343074799,
0.015544065274298191,
0.005616895854473114,
0.007861706428229809,
0.03560000658035278,
-0.025098158046603203,
-0.03... |
propriate data security features and are\ncompliant with the U.S. Health InsurancePortability and Accountability Act of 1996.\nThese programs can help monitor people\nwith diabetes and provide access to theirhealth care teams (264). Consumers\nshould read the policy regarding data pri-\nvacy and sharing before entering... | [
-0.035588886588811874,
0.07554368674755096,
-0.027295898646116257,
-0.014563660137355328,
-0.02203317917883396,
0.09612094610929489,
0.052979256957769394,
-0.019587187096476555,
-0.06248421221971512,
-0.0006558810127899051,
0.025797639042139053,
0.11931391805410385,
-0.010103601031005383,
... |
vacy and sharing before entering data into\nan application and learn how they can con-\ntrol the way their data will be used (someprograms offer the ability to share more or\nless information, such as being part of a\nregistry or data repository or not).\nMany online programs offer lifestyle\ncounseling to achieve weig... | [
-0.03447515890002251,
0.03998371586203575,
-0.047196514904499054,
0.008247002959251404,
-0.05361494794487953,
0.04620584100484848,
0.035128336399793625,
0.039019133895635605,
-0.06496340781450272,
-0.046797607094049454,
0.045164138078689575,
-0.0069212475791573524,
0.0049573746509850025,
-... |
counseling to achieve weight loss and in-\ncreased physical activity (265). Many in-\nclude a health coach and can create smallgroups of similar participants on social net-works. Some programs aim to treat predia-\nbetes and prevent progression to diabetes,\noften following the model of the DiabetesPrevention Program (... | [
-0.022702395915985107,
0.0785478800535202,
-0.023861804977059364,
0.07720634341239929,
-0.0724979043006897,
0.0732787624001503,
0.03476880118250847,
0.013057762756943703,
-0.01594349555671215,
-0.013287215493619442,
-0.04254442825913429,
0.012453158386051655,
-0.03732559457421303,
-0.01341... |
sist in improving diabetes outcomes by\nremotely monitoring clinical data (forinstance, wireless monitoring of glucose\nlevels, weight, or blood pressure) and pro-\nviding feedback and coaching (268 –273).\nThere are text messaging approaches thattie into a variety of different types of life-\nstyle and treatment progr... | [
-0.060006070882081985,
0.008403333835303783,
-0.022310756146907806,
0.024388758465647697,
-0.03091837279498577,
-0.01011162530630827,
0.046575773507356644,
0.14714273810386658,
0.030575169250369072,
-0.03235473111271858,
-0.021824778988957405,
0.08872955292463303,
-0.019118264317512512,
-0... |
style and treatment programs, which vary\nin terms of their effectiveness (274,275).There are limited RCT data for many of\nthese interventions, and long-term follow-\nup is lacking. However, for an individualwith diabetes, opting into one of these pro-grams can be helpful in providing support\nand, for many, is an att... | [
0.00622005807235837,
0.02578097954392433,
-0.004183677025139332,
0.0050652953796088696,
-0.044465262442827225,
0.05613561347126961,
0.02121255174279213,
0.17669987678527832,
-0.02078019082546234,
-0.05261819064617157,
-0.06976267695426941,
0.0631210133433342,
-0.052411749958992004,
-0.0320... |
and, for many, is an attractive option.\nInpatient Care\nRecommendations\n7.33 In people with diabetes using\npersonal CGM, the use of CGM should\nbe continued when clinically appropriateduring hospitalization, with con firmatory\npoint-of-care glucose measurements forinsulin dosing and hypoglycemia assess-ment and trea... | [
-0.038845162838697433,
0.04806940630078316,
-0.0554274246096611,
0.008775115013122559,
-0.09267808496952057,
0.050375573337078094,
0.07110604643821716,
0.12715555727481842,
-0.06851706653833389,
-0.028281277045607567,
-0.05893295630812645,
0.0014904664130881429,
-0.0712454617023468,
0.0343... |
tional protocol. B\n7.34 People with diabetes who are\ncompetent to safely use diabetes devi-\nces such as insulin pumps and CGM\nsystems should be supported to con-\ntinue using them in an inpatient set-ting or during outpatient procedures,\nwhenever possible, and when proper\nsupervision is available. E\nIndividuals ... | [
-0.021913787350058556,
0.01012010034173727,
-0.07612606883049011,
-0.04891148582100868,
-0.08353817462921143,
0.04974294826388359,
0.12019752711057663,
0.10406330972909927,
-0.06418962776660919,
0.004190254490822554,
-0.0012627692194655538,
0.03786109760403633,
-0.035114116966724396,
0.054... |
supervision is available. E\nIndividuals who are comfortable using\ntheir diabetes devices, such as insulin\npumps and CGM, should be allowed to\nuse them in an inpatient setting if they arewell enough to take care of the devices\nand have brought the necessary supplies\n(275–279). People with diabetes who are\nfamilia... | [
-0.020000161603093147,
0.061532072722911835,
-0.027361467480659485,
0.0022019697353243828,
-0.0621192529797554,
0.024565130472183228,
0.07406710088253021,
0.05252290517091751,
-0.055189862847328186,
-0.009084219112992287,
0.040505990386009216,
0.03124873898923397,
-0.08051211386919022,
0.0... |
familiar with treating their own glucose\nlevels can often adjust insulin doses more\nknowledgeably than inpatient staff whodo not personally know the individual ortheir management style. However, this\nshould occur based on the hospital ’sp o l i -\ncies for diabetes management and use of | [
0.023837167769670486,
0.06763198971748352,
-0.04861040785908699,
0.029881242662668228,
-0.07215017825365067,
-0.034170351922512054,
0.06444646418094635,
0.028765421360731125,
0.00012264565157238394,
-0.024430088698863983,
0.009320004843175411,
0.08328688889741898,
-0.052795298397541046,
0.... |
cies for diabetes management and use of\ndiabetes technology, and there should besupervision to ensure that the individual isachieving and maintaining glycemic goals\nduring acute illness in a hospitalized set- | [
-0.05309899523854256,
0.045964792370796204,
-0.013580900616943836,
0.028562312945723534,
-0.09160391241312027,
0.024469731375575066,
0.044455770403146744,
0.11028454452753067,
-0.01832609437406063,
0.006221539806574583,
-0.04645656794309616,
-0.020086759701371193,
-0.05044543743133545,
-0.... |
during acute illness in a hospitalized set-\nting where factors, such as infection, cer-tain medications, immobility, changes innutrition, and others, can impact insulinsensitivity and the insulin response(280–282).\nWith the advent of the coronavirus dis- | [
-0.0006732095498591661,
0.03832710161805153,
-0.06257444620132446,
0.0837712362408638,
0.025488628074526787,
0.019767645746469498,
0.059875376522541046,
0.13294453918933868,
-0.03340013697743416,
-0.02356467954814434,
-0.05783606693148613,
0.07138940691947937,
0.0250808447599411,
0.0765260... |
With the advent of the coronavirus dis-\nease 2019 pandemic, the FDA exercisedenforcement discretion by allowing CGMdevice use temporarily in the hospital forpatient monitoring (283). This approachhas been used to reduce the use of per-sonal protective equipment and more\nclosely monitor patients so that health | [
-0.041762642562389374,
0.06403257697820663,
-0.04737130552530289,
-0.050417810678482056,
-0.006194678600877523,
0.03643180802464485,
0.017237670719623566,
0.1469697803258896,
-0.0124028529971838,
0.018799811601638794,
-0.002222076989710331,
-0.018008574843406677,
-0.008203466422855854,
0.0... |
closely monitor patients so that health\ncare personnel do not have to go into apatient room solely to measure a glucoselevel (284 –286). Studies have been pub-\nlished assessing the effectiveness of this\napproach, which may ultimately lead to\nthe approved use of CGM for monitoringhospitalized individuals (278,287 –2... | [
-0.014949263073503971,
0.059757769107818604,
-0.07010143250226974,
0.010942731983959675,
-0.04319017007946968,
0.02319251000881195,
0.0315987691283226,
0.07153993844985962,
-0.028788963332772255,
-0.032308243215084076,
-0.019895372912287712,
-0.03184421733021736,
-0.06018204987049103,
0.05... |
When used in the setting of a clinical trialor when clinical circumstances (such asduring a shortage of personal protective\nequipment) require it, CGM can be used | [
-0.07704512029886246,
0.06265958398580551,
-0.05929572507739067,
-0.07326526939868927,
0.019933832809329033,
0.08887724578380585,
0.01998157799243927,
0.1670788824558258,
-0.0030436664819717407,
0.023430513218045235,
0.03820944204926491,
-0.033136337995529175,
-0.05974049121141434,
0.08935... |
equipment) require it, CGM can be used\nto manage hospitalized individuals in con-junction with BGM. Point-of-care BGM re-mains the approved method for glucosemonitoring in hospitals, especially fordosing insulin and treating hypoglyce-\nmia. Similarly, data are emerging on the | [
-0.05786709114909172,
0.04785751551389694,
-0.07043952494859695,
0.0003520870814099908,
-0.07619614899158478,
0.033306319266557693,
0.06273822486400604,
0.1077575832605362,
-0.06013115495443344,
-0.0067930687218904495,
-0.03424431383609772,
0.008376993238925934,
-0.0477183572947979,
0.0634... |
mia. Similarly, data are emerging on the\ninpatient use of AID systems and theirchallenges (278,297,298). For more in-formation, see Section 16, “Diabetes\nCare in the Hospital. ”\nThe Future\nThe pace of development in diabetes\ntechnology is extremely rapid. New ap-\nproaches and tools are available eachyear. It is d... | [
-0.0339055061340332,
0.002841714769601822,
-0.07333648204803467,
0.01904229074716568,
-0.0023902927059680223,
0.03431523218750954,
-0.01181930024176836,
0.0741497352719307,
-0.03141652047634125,
0.051241565495729446,
0.014155194163322449,
0.06314332038164139,
-0.05022864416241646,
0.026397... |
up with these advances because newerversions of the devices and digital solu-tions are already on the market by the\ntime a study is completed. The most\nimportant component in all of these sys-tems is the person with diabetes. Tech-nology selection must be appropriate forthe individual. Simply having a device orapplic... | [
0.008063568733632565,
-0.02324136719107628,
-0.007725083734840155,
-0.029136961326003075,
-0.03501863405108452,
-0.025992749258875847,
0.079730324447155,
0.10033214837312698,
-0.006898283492773771,
0.004270917735993862,
0.00514561403542757,
0.04302692413330078,
-0.033344969153404236,
0.028... |
unless the human being engages with it\nto create positive health bene fits. This\nunderscores the need for the health careS136 Diabetes Technology Diabetes Care Volume 47, Supplement 1, January 2024\n©AmericanDiabetesAssociation | [
-0.033164653927087784,
0.06690004467964172,
-0.0659484937787056,
0.0261469054967165,
-0.037426725029945374,
0.051857538521289825,
0.08036362379789352,
0.04585917294025421,
0.01995498314499855,
-0.01888546533882618,
-0.015285118483006954,
0.0799662321805954,
-0.04603460058569908,
0.00624020... |
8. Obesity and Weight Management\nfor the Prevention and Treatmentof Type 2 Diabetes:\nStandards of\nCare in Diabetes –2024\nDiabetes Care 2024;47(Suppl. 1):S145 –S157 |https://doi.org/10.2337/dc24-S008American Diabetes Association\nProfessional Practice Committee *\nThe American Diabetes Association (ADA) “Standards o... | [
-0.022867614403367043,
0.058870069682598114,
-0.003601280739530921,
0.11184728890657425,
-0.05082342401146889,
0.0586121566593647,
0.009432739578187466,
0.009145527146756649,
-0.09784919768571854,
-0.009732238948345184,
-0.0012377334060147405,
0.054761167615652084,
-0.09614575654268265,
-0... |
includes the ADA ’s current clinical practice recommendations and is intended to\nprovide the components of diabetes care, general treatment goals and guide-\nlines, and tools to evaluate quality of care. Members of the ADA Professional\nPractice Committee, an interprofessional expert committee, are responsible for | [
-0.050613779574632645,
-0.019235175102949142,
-0.06702178716659546,
0.061530936509370804,
-0.046361204236745834,
0.01052375603467226,
0.05657259747385979,
0.07398808002471924,
-0.059407446533441544,
-0.02808208391070366,
-0.09466734528541565,
0.006258559878915548,
-0.12005221843719482,
0.0... |
updating the Standards of Care annually, or more frequently as warranted. For adetailed description of ADA standards, statements, and reports, as well as theevidence-grading system for ADA ’s clinical practice recommendations and a full | [
-0.0784592553973198,
-0.0514310747385025,
-0.018700480461120605,
0.019980253651738167,
-0.08070966601371765,
0.012783961370587349,
-0.06993154436349869,
0.05952689051628113,
-0.10489354282617569,
0.013412732630968094,
-0.004501675255596638,
0.03631681576371193,
-0.07326127588748932,
0.0121... |
list of Professional Practice Committee members, please refer to Introductionand Methodology. Readers who wish to comment on the Standards of Care areinvited to do so at professional.diabetes.org/SOC.\nObesity is a chronic, often relapsing disease with numerous metabolic, physical, and | [
0.009814818389713764,
-0.019689379259943962,
-0.09427884221076965,
0.059080153703689575,
-0.10299740731716156,
0.026057317852973938,
0.009227484464645386,
0.0760059505701065,
-0.028746644034981728,
-0.03364374488592148,
-0.0876980572938919,
0.06385285407304764,
-0.09324980527162552,
0.0037... |
psychosocial complications, including a substantially increased risk for type 2 diabetes(1). There is strong and consistent evidence that obesity management can delay theprogression from prediabetes to type 2 diabetes (2 –6) and is highly benefi cial in treat-\ning type 2 diabetes (7 –17). In people with type 2 diabetes... | [
0.01002608984708786,
0.03885520249605179,
-0.010426496155560017,
0.12030430883169174,
-0.03158693388104439,
0.04275312274694443,
0.022977976128458977,
0.059260088950395584,
-0.04755576327443123,
0.021138710901141167,
-0.027794254943728447,
0.07060789316892624,
-0.09959755837917328,
-0.0432... |
modest weight loss improves glycemia and reduces the need for glucose-loweringmedications (7– 9), and larger weight loss substantially reduces A1C and fasting glu-\ncose and may promote sustained diabetes remission (11,18 –22). Metabolic surgery,\nwhich induces on average >20% of body weight loss, strongly improves gly... | [
-0.029069410637021065,
0.10657259821891785,
0.004508200567215681,
0.07668762654066086,
-0.006881894543766975,
0.008963881060481071,
-0.012265431694686413,
0.0673435777425766,
-0.020579157397150993,
-0.02466701902449131,
-0.02190210111439228,
0.07882208377122879,
-0.03154189512133598,
-0.04... |
often leads to remission of diabetes, improved quality of life, improved cardiovascularoutcomes, and reduced mortality (23,24). Several modalities, including intensive be-havioral and lifestyle counseling, obesity pharmacotherapy, and metabolic surgery,may aid in achieving and maintaining meaningful weight loss and red... | [
-0.017545489594340324,
0.08380042761564255,
0.01632041670382023,
0.07597953826189041,
-0.014932109043002129,
0.03564402833580971,
-0.05722181499004364,
0.002094663679599762,
-0.05436384305357933,
-0.05278979241847992,
-0.05744696408510208,
0.08570963144302368,
-0.05738210678100586,
-0.0343... |
maintaining meaningful weight loss and reducing obesity-associated health risks. This section aims to provide evidence-based recommendationsfor obesity management, including behavioral, pharmacologic, and surgical interven-tions, in people with, or at high risk of, type 2 diabetes. Additional considerations re-garding ... | [
-0.006774593610316515,
0.07511106878519058,
-0.032552238553762436,
0.0869579166173935,
-0.06288085877895355,
0.04358755797147751,
0.014796890318393707,
0.01270117424428463,
-0.13420073688030243,
-0.018016410991549492,
-0.0028717159293591976,
0.03359401971101761,
0.017848055809736252,
0.015... |
Additional considerations re-garding weight management in older individuals and children can be found in Section13,“Older Adults, ”and Section 14, “Children and Adolescents, ”respectively. | [
-0.021903175860643387,
0.07076182216405869,
0.007831963710486889,
0.09947793185710907,
-0.05803792178630829,
0.018691658973693848,
-0.008811491541564465,
-0.03138723596930504,
-0.11302302777767181,
-0.05733414739370346,
0.07051600515842438,
0.02732275053858757,
0.014044190756976604,
0.0006... |
ASSESSMENT AND MONITORING OF THE INDIVIDUAL WITH\nOVERWEIGHT AND OBESITY\nRecommendations\n8.1Use person-centered, nonjudgmental language that fosters collaboration be-\ntween individuals and health care professionals, including person- first language\n(e.g., “person with obesity ”rather than “obese person ”and“person w... | [
-0.004364602267742157,
0.07543036341667175,
-0.07326658070087433,
0.0689031109213829,
-0.058914195746183395,
0.05076463520526886,
0.08748321980237961,
0.004414220806211233,
-0.05581991374492645,
-0.03934433311223984,
0.04339873418211937,
-0.05498858168721199,
-0.031657036393880844,
-0.0048... |
rather than “diabetic person” ).E*A complete list of members of the American\nDiabetes Association Professional Practice Committeecan be found at https://doi.org/10.2337/dc24-SINT.\nDuality of interest information for each author is\navailable at https://doi.org/10.2337/dc24-SDIS.\nThis section has received endorsement... | [
0.03166904300451279,
0.02525092102587223,
-0.06301577389240265,
0.029140911996364594,
-0.0638401135802269,
0.009464931674301624,
0.11958898603916168,
0.03734443709254265,
-0.01548242662101984,
-0.039294350892305374,
-0.07114795595407486,
0.032858554273843765,
-0.12587369978427887,
-0.04003... |
This section has received endorsement from The\nObesity Society.\nSuggested citation: American Diabetes Association\nProfessional Practice Committee. 8. Obesity andweight management for the prevention andtreatment of type 2 diabetes: Standards of Care\nin Diabetes —2024 . Diabetes Care 2024;47\n(Suppl. 1):S145 –S157 | [
-0.0017181254224851727,
0.009352210909128189,
-0.04689576476812363,
0.08402901142835617,
-0.04360799118876457,
0.036674968898296356,
0.02486404962837696,
0.000660200254060328,
-0.09968378394842148,
-0.04496626555919647,
-0.023401767015457153,
0.05776425451040268,
-0.06108031049370766,
-0.0... |
in Diabetes —2024 . Diabetes Care 2024;47\n(Suppl. 1):S145 –S157\n© 2023 by the American Diabetes Association.Readers may use this article as long as thework is properly cited, the use is educationaland not for pro fit, and the work is not altered. | [
-0.06512516736984253,
0.05281754955649376,
-0.0364719033241272,
0.0423729233443737,
-0.044602274894714355,
0.03486298769712448,
-0.011574193835258484,
0.09123589843511581,
-0.028670676052570343,
-0.02474888600409031,
-0.05171571299433708,
0.15885412693023682,
-0.041764553636312485,
-0.0058... |
More information is available at https://www.diabetesjournals.org/journals/pages/license.8. OBESITY AND WEIGHT MANAGEMENTDiabetes Care Volume 47, Supplement 1, January 2024 S145\n©AmericanDiabetesAssociation | [
0.03731011599302292,
-0.023860804736614227,
-0.07150384783744812,
0.11131938546895981,
-0.03729959949851036,
0.020925505086779594,
0.015696635469794273,
0.0062511456198990345,
-0.07512611150741577,
-0.032666537910699844,
-0.030065814033150673,
0.04180597886443138,
-0.03431933745741844,
-0.... |
8.2a To support the diagnosis of\nobesity, measure height and weight\nto calculate BMI and perform addi-tional measurements of body fat distri-bution, like waist circumference, waist-\nto-hip ratio, and/or waist-to-height\nratio. E\n8.2b Monitor obesity-related anthropo-\nmetric measurements at least annuallyto inform ... | [
0.0023327323142439127,
0.08064918220043182,
0.03683019429445267,
0.05645102262496948,
-0.052022386342287064,
-0.029739031568169594,
-0.0006963015766814351,
0.13475164771080017,
-0.07355193793773651,
-0.009384668432176113,
0.00519319623708725,
-0.08961819112300873,
-0.058411672711372375,
0.... |
8.3Accommodations should be made\nto provide privacy during anthropo-metric measurements. E\n8.4In people with type 2 diabetes and\noverweight or obesity, weight manage-ment should represent a primary goalof treatment along with glycemic man-agement. A\n8.5People with diabetes and over-\nweight or obesity may bene fitf ... | [
-0.023473398759961128,
0.0915837436914444,
-0.0010806424543261528,
0.025147054344415665,
-0.03253433480858803,
0.0522398017346859,
0.08262501657009125,
0.0844014585018158,
-0.07718445360660553,
0.0004981211968697608,
0.03770878538489342,
-0.013152330182492733,
-0.0979260802268982,
-0.01336... |
weight or obesity may bene fitf r o m\nany magnitude of weight loss. Weight\nloss of 3 –7% of baseline weight im-\nproves glycemia and other intermediate\ncardiovascular risk factors. ASustained\nloss of >10% of body weight usually\nconfers greater bene fits, including dis-\nease-modifying effects and possible re-\nmissi... | [
0.011699330992996693,
0.02451005019247532,
-0.03329626843333244,
0.09452002495527267,
-0.013404587283730507,
-0.008651810698211193,
0.07196617126464844,
0.08682866394519806,
-0.060417428612709045,
0.00033381517278030515,
-0.05333440378308296,
0.007072672713547945,
-0.0004799773741979152,
-... |
mission of type 2 diabetes, and may\nimprove long-term cardiovascular out-comes and mortality. B\n8.6 Individualize initial treatment\napproaches for obesity (i.e., lifestyleand nutritional therapy, pharmaco-logic agents, or metabolic surgery) A\nbased on the person’ sm e d i c a lh i s - | [
-0.011572374030947685,
0.06061791628599167,
-0.02040850929915905,
0.006159298121929169,
-0.0438305027782917,
0.025042658671736717,
-0.021087678149342537,
0.0381661020219326,
-0.06007758900523186,
-0.0009593642898835242,
-0.0397946760058403,
0.04656089097261429,
-0.07543431222438812,
-0.035... |
based on the person’ sm e d i c a lh i s -\ntory, life circumstances, preferences,and motivation. CConsider combin-\ning treatment approaches if appropri-ate.E\nObesity is de fin e db yt h eW o r l dH e a l t h\nOrganization as an abnormal or excessive\nfat accumulation that presents a risk to\nhealth (25). BMI (calcula... | [
0.008018849417567253,
0.036219410598278046,
-0.028977833688259125,
0.036838874220848083,
-0.06542474031448364,
-0.033836446702480316,
0.08968069404363632,
0.14022621512413025,
-0.07170497626066208,
-0.008699960075318813,
0.05916915088891983,
-0.06064550206065178,
-0.04374748095870018,
0.01... |
health (25). BMI (calculated as weight\nin kilograms divided by the square ofheight in meters [kg/m\n2]) has been used\nwidely to diagnose and stage obesity(overweight: BMI 25 –29.9 kg/m\n2;o b e s i t y\nclass I: BMI 30 –34.9 kg/m2;o b e s i t yc l a s s\nII: BMI 35 –39.9 kg/m2; obesity class III:\nBMI$40 kg/m2); howe... | [
-0.0038864081725478172,
0.04106466472148895,
-0.04074309021234512,
-0.008280700072646141,
-0.03590909391641617,
-0.020673437044024467,
0.022164057940244675,
0.007392488420009613,
-0.097780741751194,
-0.00546274846419692,
0.023943258449435234,
-0.06765159219503403,
-0.028288016095757484,
-0... |
BMI$40 kg/m2); however, BMI should\nnot be relied on as a sole diagnostic andstaging tool (19). Despite its ease of mea-surement, BMI is at most an imperfect\nmeasure of adipose tissue mass and does\nnot measure adipose tissue distribution\nor function, nor does it factor in the pres- | [
0.015337017364799976,
0.07235001027584076,
-0.01018084492534399,
0.05230928584933281,
-0.0493813119828701,
-0.01780802197754383,
0.030932411551475525,
0.01473906822502613,
-0.07594520598649979,
0.01648617722094059,
0.04061983898282051,
-0.10460609942674637,
-0.017533250153064728,
-0.000132... |
or function, nor does it factor in the pres-\nence of weight-related health or well-beingconsequences (26,27). BMI is especially\nprone to misclassi fication in individuals\nwho are very muscular or frail, as well asin populations with different body com-position and cardiometabolic risk (28). A\ndiagnosis of obesity sh... | [
0.024087117984890938,
0.06462785601615906,
-0.05330662056803703,
0.07375649362802505,
-0.04188411310315132,
0.06796276569366455,
0.03469347953796387,
0.013476879335939884,
-0.06618759781122208,
-0.034121520817279816,
0.05159139633178711,
-0.03375599905848503,
-0.02671850472688675,
0.003313... |
diagnosis of obesity should be made\nbased on an overall assessment of the in-dividual ’s adipose tissue mass (BMI can\nbe used as a general guidance), distribution\n(using other anthropometric measurements\nlike waist circumference, waist-to-hip cir-cumference ratio, or waist-to-heightratio), or function and, importan... | [
0.025274261832237244,
0.04259112849831581,
-0.049576982855796814,
0.009542170912027359,
-0.03627002239227295,
0.005198704544454813,
0.012550816871225834,
0.0214920062571764,
-0.09224426001310349,
-0.01656404137611389,
-0.002878841245546937,
-0.05756230279803276,
-0.0160312931984663,
0.0223... |
presence of associated health or well-be-\ning consequences: metabolic, physical, orpsychological/well-being (29).\nO b e s i t yi sak e yp a t h o p h y s i o l o g i cd r i v e r\nof diabetes, other cardiovascular risk fac-\ntors (e.g., hypertension, hyperlipidemia,\nnonalcoholic fatty liver disease, and in-flammatory... | [
-0.00032605300657451153,
0.048302117735147476,
-0.021406441926956177,
0.07990315556526184,
0.011582150124013424,
0.04171163961291313,
-0.014277641661465168,
0.040167223662137985,
-0.04244251549243927,
-0.06227932125329971,
0.05811266973614693,
0.03978739306330681,
-0.0239840280264616,
-0.0... |
vascular and kidney disease (30). Diabetescan further exacerbate obesity, setting up\na vicious cycle that contributes to disease\nprogression and occurrence of microvascu-lar and macrovascular complications. Assuch, treatment goals for both glycemia\na n dw e i g h ta r er e c o m m e n d e di np e o p l e | [
-0.02750866487622261,
0.05838926509022713,
-0.058201856911182404,
0.00842713937163353,
-0.03774983063340187,
-0.02182355336844921,
0.0008076169178821146,
0.09260129183530807,
-0.055164679884910583,
0.04739820957183838,
-0.046731509268283844,
0.04073268547654152,
-0.04818776994943619,
-0.02... |
a n dw e i g h ta r er e c o m m e n d e di np e o p l e\nwith diabetes to address both hyperglyce-mia and its underlying pathophysiologicdriver (obesity) and therefore benefi tt h e\nperson holistically.\nA person-centered communication style | [
-0.012576891109347343,
0.038918834179639816,
-0.016020627692341805,
-0.0038907413836568594,
-0.09614851325750351,
0.010142408311367035,
0.1113772764801979,
-0.015523520298302174,
0.020451223477721214,
-0.04990825802087784,
0.009315910749137402,
0.04188091307878494,
-0.10295204073190689,
-0... |
person holistically.\nA person-centered communication style\nthat uses inclusive and nonjudgmental lan-guage and active listening to elicit individ-ual preferences and beliefs and assesses\npotential barriers to care should be used\nto optimize health outcomes and health-related quality of life. Use person- first lan- | [
0.00917474739253521,
0.026581963524222374,
-0.03674894571304321,
-0.05811205878853798,
-0.13063859939575195,
-0.01258974988013506,
0.06807233393192291,
0.01709168404340744,
-0.02239273488521576,
-0.029457081109285355,
0.07445987313985825,
0.037089597433805466,
-0.046944789588451385,
-0.038... |
guage (e.g., “person with obesity ”rather\nthan “obese person ”)t oa v o i dd e fining\npeople by their condition (26,31,32).Measurement of weight and height (tocalculate BMI) and other anthropometricmeasurements should be performed at\nleast annually to aid the diagnosis of obesity | [
-0.019592026248574257,
0.06952498853206635,
-0.04863860458135605,
0.010963641107082367,
-0.06997224688529968,
0.020883003249764442,
0.07594472169876099,
0.029890958219766617,
-0.08979771286249161,
-0.038684774190187454,
0.10736708343029022,
-0.08162709325551987,
-0.013937386684119701,
-0.0... |
least annually to aid the diagnosis of obesity\nand to monitor its progression and re-sponse to treatment (33). Clinical consider-ations, such as the presence of comorbid\nheart failure or unexplained weight change, | [
0.005817187484353781,
0.06426726281642914,
-0.013325626030564308,
0.03496193513274193,
-0.03190506622195244,
0.051967572420835495,
-0.08225040882825851,
0.04670713096857071,
-0.03793743997812271,
-0.0439935103058815,
0.013122370466589928,
-0.08117328584194183,
-0.011166349053382874,
-0.012... |
heart failure or unexplained weight change,\nmay warrant more frequent evaluation(34,35). If such measurements are ques-tioned or declined by the individual, thepractitioner should be mindful of possible\nprior stigmatizing experiences and query | [
0.051176030188798904,
0.08230636268854141,
-0.0009434241219423711,
0.06322736293077469,
-0.02574344538152218,
-0.022206012159585953,
-0.024663204327225685,
0.07797281444072723,
-0.0337427482008934,
-0.07001737505197525,
0.029127854853868484,
-0.07306817173957825,
-0.0449272021651268,
0.019... |
prior stigmatizing experiences and query\nfor concerns, and the value of monitoringshould be explained as a part of the medi-cal evaluation process that helps to inform\ntreatment decisions (36,37). Accommoda- | [
0.061315879225730896,
0.07053689658641815,
-0.04037242755293846,
0.06509820371866226,
-0.028963647782802582,
0.033408887684345245,
0.11638383567333221,
0.09478523582220078,
0.003767714137211442,
-0.03259861096739769,
0.004436998628079891,
-0.07106040418148041,
0.0205233134329319,
-0.044875... |
treatment decisions (36,37). Accommoda-\ntions should be made to ensure privacyduring weighing and other anthropometricmeasurements, particularly for those indi-viduals who report or exhibit a high levelof disease-related distress or dissatisfaction.Anthropometric measurements should be\nperformed and reported nonjudgm... | [
0.029735127463936806,
0.06845249235630035,
-0.05593530088663101,
0.046671945601701736,
-0.10069405287504196,
0.019854476675391197,
0.046916667371988297,
0.09685035049915314,
-0.09767695516347885,
0.02347167581319809,
0.0812440887093544,
-0.0761743113398552,
-0.047420233488082886,
-0.001184... |
performed and reported nonjudgmentally;\nsuch information should be regarded assensitive health information.\nHealth care professionals should advise | [
0.010857629589736462,
0.10675854980945587,
-0.06853603571653366,
0.006503347773104906,
-0.10400243103504181,
0.03741326928138733,
0.01443430781364441,
0.05815763771533966,
-0.05878865346312523,
-0.041426051408052444,
0.03657139465212822,
0.02109828218817711,
-0.0378497838973999,
0.01317460... |
Health care professionals should advise\nindividuals with overweight or obesity andthose with increasing weight trajectoriesthat, in general, greater fat accumulationincreases the risk of diabetes, cardiovascu-lar disease, and all-cause mortality and has\nmultiple adverse health and quality of life | [
0.0037538097240030766,
-0.02023468166589737,
-0.02069169096648693,
0.07028914988040924,
-0.09235600382089615,
-0.0009502211469225585,
-0.0024808531161397696,
0.09245897084474564,
-0.09041859209537506,
-0.030825713649392128,
0.0030545012559741735,
0.0236298069357872,
-0.07646974921226501,
-... |
multiple adverse health and quality of life\nconsequences. Health care professionalsshould assess readiness to engage in be-havioral changes for weight loss and jointly\ndetermine behavioral and weight loss\ngoals and individualized interventionstrategies using shared decision-making(38). Strategies may include nutriti... | [
0.062407486140728,
0.059718649834394455,
-0.015767628327012062,
0.06924847513437271,
-0.054183535277843475,
0.08227667212486267,
-0.02818693220615387,
0.04872804135084152,
-0.10015901923179626,
0.012982141226530075,
0.02884114533662796,
-0.03176596760749817,
-0.04437899589538574,
-0.052374... |
dietary changes, physical activity and ex-\nercise, behavioral counseling, pharmaco-therapy, medical devices, and metabolicsurgery. The initial and subsequent thera-\npeutic choice should be individualized\nbased on the person’ s medical history, life | [
-0.004296300001442432,
0.09190370887517929,
-0.013577328994870186,
0.019779127091169357,
-0.0644533708691597,
0.06687771528959274,
0.023609904572367668,
0.032326530665159225,
-0.05451004207134247,
0.0068419864401221275,
0.043895404785871506,
0.03402314707636833,
-0.12570372223854065,
-0.00... |
based on the person’ s medical history, life\ncircumstances, preferences, and motiva-tion (39). Combination treatment ap-proaches may be appropriate in higher-\nrisk individuals.\nAmong people with type 2 diabetes\nand overweight or obesity who have in-\nadequate glycemic, blood pressure, andlipid management and/or oth... | [
-0.00019621425599325448,
0.0761454850435257,
-0.051171038299798965,
-0.0032357044983655214,
-0.12858054041862488,
-0.005489087197929621,
0.07932651787996292,
0.06612329930067062,
-0.07849203795194626,
-0.013126811943948269,
0.036345332860946655,
0.06281556189060211,
-0.06398703157901764,
-... |
related metabolic complications, modest\nand sustained weight loss (3 –7% of body\nweight) improves glycemia, blood pres-sure, and lipids and may reduce the need\nfor disease-speci fic medications (7 –9,40). In\npeople at risk, 3 –7% weight loss reduces\nprogression to diabetes (2,7,8,41,42).\nGreater weight loss may pr... | [
-0.03479854017496109,
0.06616698950529099,
-0.008251088671386242,
0.0845121368765831,
-0.024312203750014305,
-0.007814235985279083,
0.011408631689846516,
0.14624106884002686,
-0.06716230511665344,
-0.04649123176932335,
0.013745389878749847,
-0.01777750626206398,
-0.05186930671334267,
-0.03... |
Greater weight loss may produce addi-\ntional bene fits (20,21). Mounting data\nhave shown that >10% body weight loss\nusually confers greater benefi ts on glyce-\nmia and possibly diabetes remission andimproves other metabolic comorbidities, | [
-0.01645890809595585,
0.0131474444642663,
0.013733278028666973,
0.08654648810625076,
-0.01674916408956051,
0.02152327261865139,
0.04061192274093628,
0.08795979619026184,
-0.0587787851691246,
-0.02640872821211815,
0.00997877586632967,
0.03330124914646149,
-0.02415352687239647,
-0.0325945839... |
including cardiovascular outcomes, nonal-coholic steatohepatitis, nonalcoholic fattyliver disease, adipose tissue in flamma-\ntion, and sleep apnea, as well as physical\ncomorbidities and quality of life (6,20,\n21,30,41,43 –52).\nWith the increasing availability of more\neffective treatments, individuals with dia-betes... | [
0.046005554497241974,
0.010940312407910824,
-0.03414784371852875,
0.04583063721656799,
-0.05792886018753052,
0.02551763318479061,
-0.06887944042682648,
0.014164149761199951,
-0.029733696952462196,
0.010450627654790878,
0.019513418897986412,
0.06058860570192337,
-0.05488264933228493,
-0.023... |
be informed of the potential benefi ts of\nboth modest and more substantial weightS146 Obesity and Weight Management for Type 2 Diabetes Diabetes Care Volume 47, Supplement 1, January 2024\n©AmericanDiabetesAssociation | [
0.009027980268001556,
0.034101322293281555,
-0.007210285868495703,
0.09703061729669571,
-0.03554798662662506,
0.015188708901405334,
0.036814186722040176,
0.11824370920658112,
-0.09498025476932526,
-0.05241014435887337,
-0.011037805117666721,
-0.0393349826335907,
-0.024152789264917374,
-0.0... |
l o s sa n dg u i d e di nt h er a n g eo fa v a i l a b l e\ntreatment options, as discussed in thesections below. Shared decision-makingshould be used when counseling onbehavioral changes, intervention choices,and weight management goals.\nNUTRITION, PHYSICAL ACTIVITY,\nAND BEHAVIORAL THERAPY\nRecommendations\n8.7Nut... | [
-0.0028933691792190075,
0.045880015939474106,
-0.03576112911105156,
0.053841590881347656,
-0.07088306546211243,
0.06785546243190765,
0.031581979244947433,
0.0377018116414547,
-0.06455356627702713,
0.03063066303730011,
0.032923340797424316,
0.003135044826194644,
-0.06089380383491516,
0.0250... |
Recommendations\n8.7Nutrition, physical activity, and\nbehavioral therapy to achieve and\nmaintain $5% weight loss are rec-\nommended for people with type 2diabetes and overweight or obesity. B\n8.8a Interventions including high fre-\nquency of counseling ( $16 sessions | [
-0.01599564403295517,
0.01727048121392727,
0.02627633884549141,
0.09953504055738449,
-0.07745857536792755,
0.0773589238524437,
0.06260887533426285,
0.01145109161734581,
-0.05869942530989647,
0.018140623345971107,
-0.04629673436284065,
0.00015324444393627346,
-0.09457384049892426,
0.0065962... |
quency of counseling ( $16 sessions\nin 6 months) with focus on nutritionchanges, physical activity, and be-havioral strategies to achieve a\n500– 750 kcal/day energy defi cit have\nbeen shown to be bene ficial for weight\nloss and should be considered whenavailable. A\n8.8b Consider structured programs de-\nlivering beh... | [
-0.0203628558665514,
0.06802239269018173,
-0.027371209114789963,
0.09024877846240997,
-0.1321934312582016,
0.04835600405931473,
0.044092439115047455,
0.0010841205948963761,
-0.03941277042031288,
-0.005999802611768246,
0.0012051002122461796,
-0.08577282726764679,
-0.0500224269926548,
-0.008... |
livering behavioral counseling (face-to-\nface or remote) to address barriers to\naccess. E\n8.9Nutrition recommendations should\nbe individualized to the person’ sp r e f -\nerences and nutritional needs. Use nu-tritional plans that create an energy\ndeficit, regardless of macronutrient\ncomposition, to achieve weight ... | [
0.003271197434514761,
0.03375832736492157,
-0.05766623094677925,
0.051923323422670364,
-0.05950336158275604,
0.06961243599653244,
-0.022276567295193672,
0.08600419759750366,
-0.1086466833949089,
-0.04782305285334587,
0.01650390215218067,
-0.08745580911636353,
-0.07418578118085861,
0.004442... |
composition, to achieve weight loss. A\n8.10 When developing a plan of care,\nconsider systemic, structural, and so-cioeconomic factors that may impactnutrition patterns and food choices,\nsuch as food insecurity and hunger,\naccess to healthful food options, cul-tural circumstances, and other social\ndeterminants of h... | [
0.027683641761541367,
0.06022152304649353,
0.01310179103165865,
0.07919241487979889,
-0.05366948992013931,
0.10704636573791504,
0.010471941903233528,
0.06407725065946579,
-0.04831109941005707,
-0.0326475091278553,
0.05943163111805916,
-0.04639361798763275,
-0.06383950263261795,
-0.07537961... |
determinants of health. C\n8.11a For those who achieve weight\nloss goals, long-term ( $1y e a r )w e i g h t\nmaintenance programs are recom-mended, when available. Effective pro-\ngrams provide monthly contact andsupport, recommend ongoing monitor-\ning of body weight (weekly or more | [
-0.021848628297448158,
0.047596294432878494,
-0.021573424339294434,
0.030195867642760277,
-0.030701005831360817,
0.08464603871107101,
0.0438648983836174,
0.07912227511405945,
-0.07085410505533218,
0.0010548371355980635,
0.021455951035022736,
-0.07369040697813034,
-0.059663236141204834,
-0.... |
ing of body weight (weekly or more\nfrequently) and other self-monitoringstrategies, and encourage regular phys-\nical activity (200 –300 min/week). A\n8.11b For those who achieve weight\nloss goals, continue to monitor prog-\nress periodically, provide ongoing sup-\nport, and recommend continuing | [
-0.020868968218564987,
0.05068472772836685,
0.009995091706514359,
0.04176511615514755,
-0.02575346641242504,
0.028065189719200134,
0.03475209325551987,
0.016614260151982307,
-0.07377522438764572,
-0.04089582338929176,
-0.012432721443474293,
-0.0440593883395195,
-0.05278123915195465,
0.0178... |
port, and recommend continuing\nadopted interventions to maintaingoals long term. E8.12 When short-term nutrition inter-\nvention using structured, very-low-\ncalorie meals (800 –1,000 kcal/day) is | [
0.022279031574726105,
0.07834389060735703,
0.026975838467478752,
0.06028524413704872,
-0.11449180543422699,
0.031034570187330246,
-0.052014708518981934,
0.06660351157188416,
-0.07842396199703217,
-0.10390209406614304,
0.0807352215051651,
0.004419068805873394,
-0.04967194050550461,
-0.06102... |
calorie meals (800 –1,000 kcal/day) is\nconsidered, it should be prescribed tocarefully selected individuals by trainedpractitioners in medical settings withclose monitoring. Long-term, compre-hensive weight maintenance strategiesand counseling should be integratedto maintain weight loss. B\n8.13 Nutritional supplement... | [
-0.007534236181527376,
0.06942146271467209,
-0.0013106951955705881,
0.005161625798791647,
-0.06482484936714172,
0.02915831096470356,
0.03948250040411949,
0.030762918293476105,
-0.01884991116821766,
-0.07271376997232437,
0.01883913204073906,
-0.05218786746263504,
-0.027045268565416336,
-0.0... |
8.13 Nutritional supplements have not\nbeen shown to be effective for weightloss and are not recommended. A\nFor a more detailed discussion of life-\nstyle management approaches and rec-\nommendations, see Section 5, “Facilitating\nPositive Health Behaviors and Well-being\nto Improve Health Outcomes. ”For a de- | [
-0.06290808320045471,
0.05674413591623306,
0.0033225647639483213,
0.03760598599910736,
-0.027141740545630455,
0.016171904280781746,
-0.0005239714519120753,
0.07790792733430862,
-0.05645255744457245,
-0.08117039501667023,
0.08205153793096542,
0.04769730567932129,
-0.04323512315750122,
-0.01... |
to Improve Health Outcomes. ”For a de-\ntailed discussion of nutrition interventions,please also refer to “Nutrition Therapy for\nAdults With Diabetes or Pre-diabetes: A\nConsensus Report ”(53).\nLook AHEAD Trial\nAlthough the Action for Health in Diabetes\n(Look AHEAD) trial did not show that the\nintensive lifestyle ... | [
-0.03132764250040054,
0.08496691286563873,
0.026353146880865097,
0.0629349872469902,
-0.0055857133120298386,
0.06503552943468094,
-0.014688373543322086,
0.03816225379705429,
-0.01778748817741871,
-0.031840961426496506,
0.01978803239762783,
0.10696566104888916,
-0.0752963125705719,
-0.09518... |
intensive lifestyle intervention reduced\ncardiovascular events in adults with type 2\ndiabetes and overweight or obesity (41), itdid con firm the feasibility of achieving and\nmaintaining long-term weight loss in peo-\nple with type 2 diabetes. In the intensive\nlifestyle intervention group, mean weight | [
0.03182942420244217,
0.07663369923830032,
0.05087575688958168,
0.06183399632573128,
0.002546977251768112,
-0.01877426728606224,
-0.034387797117233276,
0.10854534059762955,
-0.08993694186210632,
0.0015190955018624663,
-0.0035594371147453785,
0.03163744509220123,
-0.03800617903470993,
-0.017... |
lifestyle intervention group, mean weight\nloss was 4.7% at 8 years (42). Approxi-mately 50% of intensive lifestyle interven-\ntion participants lost and maintained $5%\nof their initial body weight, and 27% lostand maintained $10% of their initial body\nweight at 8 years (42). Participants as-\nsigned to the intensive... | [
0.023700209334492683,
0.07565103471279144,
0.027103012427687645,
0.1254226714372635,
-0.039972975850105286,
0.035302188247442245,
-0.07487514615058899,
0.11690765619277954,
-0.125278502702713,
-0.04029862955212593,
0.07744747400283813,
-0.057406071573495865,
0.008920001797378063,
-0.002693... |
signed to the intensive lifestyle group re-\nquired fewer glucose-, blood pressure-,\nand lipid-lowering medications than those\nrandomly assigned to standard care. Sec-\nondary analyses of the Look AHEAD trialand other large cardiovascular outcome\nstudies document additional weight loss\nbenefits in people with type 2... | [
-0.0316556952893734,
0.06529787182807922,
0.004505939316004515,
0.0582115463912487,
-0.011358908377587795,
0.025596117600798607,
-0.1010630875825882,
0.07039181888103485,
-0.053180817514657974,
-0.03986281529068947,
-0.053489115089178085,
0.059187404811382294,
-0.08481385558843613,
-0.0562... |
benefits in people with type 2 diabetes, in-\ncluding improved mobility, physical and\nsexual function, and health-related quality\nof life (34). Moreover, several subgroups\nhad improved cardiovascular outcomes,\nincluding those who achieved >10%\nweight loss (43).\nBehavioral Interventions\nSignificant weight loss can ... | [
0.015001638792455196,
0.08201829344034195,
-0.009755917824804783,
0.04499835893511772,
-0.055495485663414,
0.04001596197485924,
0.031499721109867096,
0.028382759541273117,
-0.08103872090578079,
-0.019708525389432907,
-0.013311516493558884,
0.0491197407245636,
-0.058104828000068665,
-0.0613... |
Behavioral Interventions\nSignificant weight loss can be attained\nwith lifestyle programs that achieve a500–750 kcal/day energy de ficit, which\nin most cases is approximately 1,200 –\n1,500 kcal/day for women and 1,500 –\n1,800 kcal/day for men, adjusted for the\nindividual ’s baseline body weight. Clinical\nbenefits ty... | [
-0.0066221533343195915,
0.10152959078550339,
0.01406191661953926,
0.053394317626953125,
-0.10234460234642029,
0.005282140336930752,
-0.02139762043952942,
0.04571366310119629,
-0.07711310684680939,
-0.002789079211652279,
-0.03893362730741501,
-0.0333540141582489,
-0.029270155355334282,
-0.0... |
benefits typically begin upon achieving 5%\nweight loss (19,54), and the bene fits of\nweight loss are progressive; more inten-sive weight loss goals ( >7%,>10%,\n>15%, etc.) may be pursued to achieve\nfurther health improvements if the indi-vidual is motivated and more intensivegoals can be feasibly and safely attained. | [
0.05369798094034195,
0.03278167545795441,
-0.01815190725028515,
0.005530226044356823,
-0.015753498300909996,
0.0396680049598217,
-0.02934388257563114,
0.07756564021110535,
-0.04676409438252449,
-0.01583428494632244,
-0.009994255378842354,
0.002849346259608865,
-0.020778486505150795,
-0.013... |
Nutrition interventions may differ by\nmacronutrient goals and food choices aslong as they create the necessary energydeficit to promote weight loss (19,55 –57).\nUsing meal replacement plans prescribed\nby trained practitioners, with close moni-\ntoring, can be bene ficial. Within the inten- | [
-0.027273941785097122,
0.056780945509672165,
0.00235474924556911,
0.032459937036037445,
-0.016097502782940865,
0.011849070899188519,
-0.058544453233480453,
0.01894284412264824,
-0.04709753394126892,
-0.11297331750392914,
0.010284113697707653,
-0.025258459150791168,
-0.017076672986149788,
-... |
toring, can be bene ficial. Within the inten-\nsive lifestyle intervention group of theLook AHEAD trial, for example, the use of\na partial meal replacement plan was asso-\nciated with improvements in nutritionquality and weight loss (54), and improve-ment in cardiovascular risk factors (41). In\na systematic review and... | [
0.023154469206929207,
0.0867772176861763,
0.01885358802974224,
0.025806032121181488,
-0.02522212080657482,
0.03582461550831795,
-0.06811589002609253,
0.06393475085496902,
-0.06334014236927032,
-0.012648236937820911,
-0.005231082905083895,
0.009800812229514122,
-0.05409178137779236,
-0.0694... |
a systematic review and meta-analysis, ef-\nficacy and safety of meal replacements\n(partial or total meal replacement) as com-pared with conventional diets showed im-provements in A1C, FBG, body weight,\nand BMI (58). The nutrition choice should\nbe based on the individual ’s health status | [
0.03253980353474617,
0.04257834702730179,
-0.012361224740743637,
0.0049351840279996395,
-0.02441210113465786,
0.0028379352297633886,
0.005180229898542166,
0.06866199523210526,
-0.0426798090338707,
-0.016286037862300873,
0.007224581204354763,
-0.042224034667015076,
-0.06571751832962036,
-0.... |
be based on the individual ’s health status\nand preferences, including a determina-tion of food availability and other cultural\ncircumstances that could affect nutrition\npatterns (59).\nProven intensive behavioral interventions\nincluded $16 sessions during an initial\n6 months and focus on nutritional changes, | [
0.052065808326005936,
0.11379138380289078,
-0.02461131662130356,
0.057860761880874634,
-0.09905639290809631,
0.10524161159992218,
-0.015671325847506523,
0.052631720900535583,
-0.12585480511188507,
-0.038742419332265854,
0.03259161859750748,
-0.04485956206917763,
-0.04641260206699371,
-0.05... |
6 months and focus on nutritional changes,\nphysical activity, and behavioral strategies\nto achieve an /C24500– 750 kcal/day energy\ndeficit. Such interventions should be pro-\nvided by trained individuals and can be\nconducted in either individual or group\nsessions (54). Assessing a person ’sm o t i - | [
-0.003760649124160409,
0.07008793950080872,
-0.009993722662329674,
0.09066328406333923,
-0.07108256220817566,
0.04202619194984436,
-0.029464736580848694,
0.04064987227320671,
-0.10217179358005524,
-0.041969530284404755,
-0.006946098990738392,
-0.03250325843691826,
-0.08356957137584686,
-0.... |
sessions (54). Assessing a person ’sm o t i -\nvation level, life circumstances, and will-ingness to implement behavioral changes\nto achieve weight loss should be consid-\nered along with medical status whensuch interventions are recommendedand initiated (38,60). If such intensive be-havioral interventions are not ava... | [
0.0035178018733859062,
0.13966569304466248,
-0.028649618849158287,
0.023287348449230194,
-0.056421369314193726,
0.10056524723768234,
0.030286308377981186,
0.07915784418582916,
-0.05441095679998398,
-0.014321507886052132,
-0.0073506999760866165,
-0.0028801620937883854,
-0.015514872968196869,
... |
accessible, structured programs deliver-\ning behavioral counseling (face-to-face orremote) can be considered; however,their effectiveness varies (61,62).\nPeople with type 2 diabetes and over-\nweight or obesity who have lost weightshould be offered long-term ( $1 year)diabetesjournals.org/care Obesity and Weight Mana... | [
-0.017214259132742882,
0.05642927065491676,
-0.039343465119600296,
0.08026675879955292,
-0.09816739708185196,
0.051053594797849655,
-0.022355448454618454,
0.0024177036248147488,
-0.07555385679006577,
-0.017273416742682457,
-0.026841316372156143,
0.04005874693393707,
-0.03202783316373825,
0... |
©AmericanDiabetesAssociation | [
0.06342031806707382,
-0.04462772607803345,
-0.07223597913980484,
0.043682683259248734,
-0.045854225754737854,
-0.0014199750730767846,
-0.005912777967751026,
-0.07833275198936462,
-0.04720243066549301,
0.09212949872016907,
0.0628901943564415,
-0.04908110201358795,
0.0067015099339187145,
0.0... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.